{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:23:20Z","timestamp":1790270600139,"version":"4.1.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T00:00:00Z","timestamp":1625788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T00:00:00Z","timestamp":1625788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s13300-021-01104-z","type":"journal-article","created":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T19:03:46Z","timestamp":1625857426000},"page":"2249-2261","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["SGLT2 Inhibitors and the Clinical Implications of Associated Weight Loss in Type\u00a02 Diabetes: A Narrative Review"],"prefix":"10.1007","volume":"12","author":[{"given":"Andrej","family":"Jane\u017e","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Fioretto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,9]]},"reference":[{"key":"1104_CR1","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.3390\/nu12092806","volume":"12","author":"E Altobelli","year":"2020","unstructured":"Altobelli E, Angeletti PM, Profeta VF, Petrocelli R. Lifestyle risk factors for type\u00a02 diabetes mellitus and national diabetes care systems in European countries. Nutrients. 2020;12:2806.","journal-title":"Nutrients"},{"key":"1104_CR2","unstructured":"International Diabetes Federation. IDF Diabetes Atlas, 9th Edition. Brussels, Belgium: International Diabetes Federation; 2019"},{"key":"1104_CR3","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1159\/000480525","volume":"10","author":"DR Leitner","year":"2017","unstructured":"Leitner DR, Fr\u00fchbeck G, Yumuk V, et al. Obesity and type\u00a02 diabetes: two diseases with a need for combined treatment strategies\u2014EASO can lead the way. Obes Facts. 2017;10:483\u201392.","journal-title":"Obes Facts"},{"key":"1104_CR4","doi-asserted-by":"publisher","first-page":"487","DOI":"10.2337\/dci19-0066","volume":"43","author":"JB Buse","year":"2020","unstructured":"Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: management of hyperglycemia in type\u00a02 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020;43:487\u201393.","journal-title":"Diabetes Care"},{"key":"1104_CR5","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1172\/JCI116972","volume":"93","author":"Y Kanai","year":"1994","unstructured":"Kanai Y, Lee WS, You G, Brown D, Hediger MA. The human kidney low affinity Na+\/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for d-glucose. J Clin Invest. 1994;93:397\u2013404.","journal-title":"J Clin Invest"},{"key":"1104_CR6","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1152\/physrev.00055.2009","volume":"91","author":"EM Wright","year":"2011","unstructured":"Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev. 2011;91:733\u201394.","journal-title":"Physiol Rev"},{"key":"1104_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/dom.13650","volume":"21","author":"E Brown","year":"2019","unstructured":"Brown E, Rajeev SP, Cuthbertson DJ, Wilding JPH. A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium-glucose co-transporter-2 inhibitors. Diabetes Obes Metab. 2019;21:9\u201318.","journal-title":"Diabetes Obes Metab"},{"key":"1104_CR8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/dom.12578","volume":"18","author":"SP Rajeev","year":"2016","unstructured":"Rajeev SP, Cuthbertson DJ, Wilding JP. Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition. Diabetes Obes Metab. 2016;18:125\u201334.","journal-title":"Diabetes Obes Metab"},{"key":"1104_CR9","doi-asserted-by":"publisher","first-page":"3324","DOI":"10.2337\/db13-0604","volume":"62","author":"MA Abdul-Ghani","year":"2013","unstructured":"Abdul-Ghani MA, DeFronzo RA, Norton L. Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30\u201350% of filtered glucose load in humans. Diabetes. 2013;62:3324\u20138.","journal-title":"Diabetes"},{"key":"1104_CR10","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1111\/obr.12841","volume":"20","author":"E Brown","year":"2019","unstructured":"Brown E, Wilding JPH, Barber TM, Alam U, Cuthbertson DJ. Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type\u00a02 diabetes mellitus and obesity: mechanistic possibilities. Obes Rev. 2019;20:816\u201328.","journal-title":"Obes Rev"},{"key":"1104_CR11","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/S0140-6736(11)60812-X","volume":"378","author":"KD Hall","year":"2011","unstructured":"Hall KD, Sacks G, Chandramohan D, et al. Quantification of the effect of energy imbalance on bodyweight. Lancet. 2011;378:826\u201337.","journal-title":"Lancet"},{"key":"1104_CR12","doi-asserted-by":"publisher","first-page":"890","DOI":"10.2337\/db10-1328","volume":"60","author":"MJ Jurczak","year":"2011","unstructured":"Jurczak MJ, Lee HY, Birkenfeld AL, et al. SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes. 2011;60:890\u20138.","journal-title":"Diabetes"},{"key":"1104_CR13","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1038\/oby.2012.59","volume":"20","author":"JJ Devenny","year":"2012","unstructured":"Devenny JJ, Godonis HE, Harvey SJ, Rooney S, Cullen MJ, Pelleymounter MA. Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats. Obesity (Silver Spring). 2012;20:1645\u201352.","journal-title":"Obesity (Silver Spring)"},{"key":"1104_CR14","doi-asserted-by":"publisher","first-page":"e30555","DOI":"10.1371\/journal.pone.0030555","volume":"7","author":"Y Liang","year":"2012","unstructured":"Liang Y, Arakawa K, Ueta K, et al. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS ONE. 2012;7:e30555.","journal-title":"PLoS ONE"},{"key":"1104_CR15","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1002\/oby.21653","volume":"24","author":"D Polidori","year":"2016","unstructured":"Polidori D, Sanghvi A, Seeley RJ, Hall KD. How strongly does appetite counter weight loss? Quantification of the feedback control of human energy intake. Obesity (Silver Spring). 2016;24:2289\u201395.","journal-title":"Obesity (Silver Spring)"},{"key":"1104_CR16","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1172\/JCI72227","volume":"124","author":"E Ferrannini","year":"2014","unstructured":"Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type\u00a02 diabetic patients. J Clin Invest. 2014;124:499\u2013508.","journal-title":"J Clin Invest"},{"key":"1104_CR17","doi-asserted-by":"publisher","first-page":"e013539","DOI":"10.1136\/bmjopen-2016-013539","volume":"7","author":"SP Rajeev","year":"2017","unstructured":"Rajeev SP, Sprung VS, Roberts C, et al. Compensatory changes in energy balance during dapagliflozin treatment in type\u00a02 diabetes mellitus: a randomised double-blind, placebo-controlled, cross-over trial (ENERGIZE)\u2014study protocol. BMJ Open. 2017;7:e013539.","journal-title":"BMJ Open"},{"key":"1104_CR18","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1507\/endocrj.EJ19-0013","volume":"66","author":"R Kosugi","year":"2019","unstructured":"Kosugi R, Nakatani E, Okamoto K, Aoshima S, Arai H, Inoue T. Effects of sodium-glucose cotransporter 2 inhibitor (dapagliflozin) on food intake and plasma fibroblast growth factor 21 levels in type\u00a02 diabetes patients. Endocr J. 2019;66:677\u201382.","journal-title":"Endocr J"},{"key":"1104_CR19","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40265-014-0337-y","volume":"75","author":"AJ Scheen","year":"2015","unstructured":"Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type\u00a02 (SGLT2) inhibitors for the treatment of type\u00a02 diabetes mellitus. Drugs. 2015;75:33\u201359.","journal-title":"Drugs"},{"key":"1104_CR20","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12933-015-0297-x","volume":"14","author":"P Fioretto","year":"2015","unstructured":"Fioretto P, Giaccari A, Sesti G. Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus. Cardiovasc Diabetol. 2015;14:142.","journal-title":"Cardiovasc Diabetol"},{"key":"1104_CR21","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/dom.12459","volume":"17","author":"S Del Prato","year":"2015","unstructured":"Del Prato S, Nauck M, Dur\u00e1n-Garcia S, et al. Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type\u00a02 diabetes: 4-year data. Diabetes Obes Metab. 2015;17:581\u201390.","journal-title":"Diabetes Obes Metab"},{"key":"1104_CR22","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1210\/jc.2011-2260","volume":"97","author":"J Bolinder","year":"2012","unstructured":"Bolinder J, Ljunggren \u00d6, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type\u00a02 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97:1020\u201331.","journal-title":"J Clin Endocrinol Metab"},{"key":"1104_CR23","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/dom.12189","volume":"16","author":"J Bolinder","year":"2014","unstructured":"Bolinder J, Ljunggren \u00d6, Johansson L, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type\u00a02 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab. 2014;16:159\u201369.","journal-title":"Diabetes Obes Metab"},{"key":"1104_CR24","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type\u00a02 diabetes. N Engl J Med. 2017;377:644\u201357.","journal-title":"N Engl J Med"},{"key":"1104_CR25","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type\u00a02 diabetes and nephropathy. N Engl J Med. 2019;380:2295\u2013306.","journal-title":"N Engl J Med"},{"key":"1104_CR26","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type\u00a02 diabetes. N Engl J Med. 2019;380:347\u201357.","journal-title":"N Engl J Med"},{"key":"1104_CR27","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.117.028268","volume":"137","author":"C Wanner","year":"2018","unstructured":"Wanner C, Lachin JM, Inzucchi SE, et al. Empagliflozin and clinical outcomes in patients with type\u00a02 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation. 2018;137:119\u201329.","journal-title":"Circulation"},{"key":"1104_CR28","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","volume":"383","author":"CP Cannon","year":"2020","unstructured":"Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular outcomes with ertugliflozin in type\u00a02 diabetes. N Engl J Med. 2020;383:1425\u201335.","journal-title":"N Engl J Med"},{"key":"1104_CR29","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1111\/dom.13920","volume":"22","author":"T Ohkuma","year":"2020","unstructured":"Ohkuma T, Van Gaal L, Shaw W, et al. Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS program. Diabetes Obes Metab. 2020;22:530\u20139.","journal-title":"Diabetes Obes Metab"},{"key":"1104_CR30","doi-asserted-by":"publisher","first-page":"384","DOI":"10.2215\/CJN.15260920","volume":"16","author":"M Jardine","year":"2021","unstructured":"Jardine M, Zhou Z, Lambers Heerspink HJ, et al. Kidney, cardiovascular, and safety outcomes of canagliflozin according to baseline albuminuria: a CREDENCE secondary analysis. Clin J Am Soc Nephrol. 2021;16:384\u201395.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1104_CR31","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/S0735-1097(20)31287-0","volume":"75","author":"K Oyama","year":"2020","unstructured":"Oyama K, Raz I, Cahn A, et al. Effects of dapagliflozin on cardiovascular outcomes across body mass index categories in patients with type\u00a02 diabetes mellitus in the DECLARE TIMI\u00a058 trial. J Am Coll Cardiol. 2020;75:660.","journal-title":"J Am Coll Cardiol"},{"key":"1104_CR32","doi-asserted-by":"publisher","first-page":"3401","DOI":"10.1002\/ehf2.12891","volume":"7","author":"P Pellicori","year":"2020","unstructured":"Pellicori P, Ofstad AP, Fitchett D, et al. Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA-REG OUTCOME. ESC Heart Fail. 2020;7:3401\u20137.","journal-title":"ESC Heart Fail"},{"key":"1104_CR33","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1111\/dom.13631","volume":"21","author":"S Gallo","year":"2019","unstructured":"Gallo S, Charbonnel B, Goldman A, et al. Long-term efficacy and safety of ertugliflozin in patients with type\u00a02 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial. Diabetes Obes Metab. 2019;21:1027\u201336.","journal-title":"Diabetes Obes Metab"},{"key":"1104_CR34","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1002\/oby.22748","volume":"28","author":"SB Heymsfield","year":"2020","unstructured":"Heymsfield SB, Raji A, Gallo S, et al. Efficacy and safety of ertugliflozin in patients with overweight and obesity with type\u00a02 diabetes mellitus. Obesity (Silver Spring). 2020;28:724\u201332.","journal-title":"Obesity (Silver Spring)"},{"key":"1104_CR35","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","volume":"5","author":"GD Lopaschuk","year":"2020","unstructured":"Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. JACC Basic Transl Sci. 2020;5:632\u201344.","journal-title":"JACC Basic Transl Sci"},{"key":"1104_CR36","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/S2213-8587(20)30038-3","volume":"8","author":"OR Ghosh-Swaby","year":"2020","unstructured":"Ghosh-Swaby OR, Goodman SG, Leiter LA, et al. Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type\u00a02 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2020;8:418\u201335.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1104_CR37","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1007\/s13300-020-00912-z","volume":"11","author":"M Qiu","year":"2020","unstructured":"Qiu M, Ding LL, Zhang M, Lin JH, Wei XB, Huang H. GLP-1RAs and SGLT2is reduce cardiovascular events independent of reductions of systolic blood pressure and body weight: a meta-analysis with meta-regression. Diabetes Ther. 2020;11:2429\u201340.","journal-title":"Diabetes Ther"},{"key":"1104_CR38","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/ki.2013.356","volume":"85","author":"DE Kohan","year":"2014","unstructured":"Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with type\u00a02 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014;85:962\u201371.","journal-title":"Kidney Int"},{"key":"1104_CR39","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436\u201346.","journal-title":"N Engl J Med"},{"key":"1104_CR40","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJMoa1212914","volume":"369","author":"RR Wing","year":"2013","unstructured":"Wing RR, Bolin P, Brancati FL, et al. Cardiovascular effects of intensive lifestyle intervention in type\u00a02 diabetes. N Engl J Med. 2013;369:145\u201354.","journal-title":"N Engl J Med"},{"key":"1104_CR41","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1002\/oby.21358","volume":"23","author":"DA Williamson","year":"2015","unstructured":"Williamson DA, Bray GA, Ryan DH. Is 5% weight loss a satisfactory criterion to define clinically significant weight loss? Obesity (Silver Spring). 2015;23:2319\u201320.","journal-title":"Obesity (Silver Spring)"},{"key":"1104_CR42","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.2337\/db15-1356","volume":"65","author":"E Ferrannini","year":"2016","unstructured":"Ferrannini E, Baldi S, Frascerra S, et al. Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type\u00a02 diabetes. Diabetes. 2016;65:1190\u20135.","journal-title":"Diabetes"},{"key":"1104_CR43","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12933-017-0658-8","volume":"17","author":"T Sato","year":"2018","unstructured":"Sato T, Aizawa Y, Yuasa S, et al. The effect of dapagliflozin treatment on epicardial adipose tissue volume. Cardiovasc Diabetol. 2018;17:6.","journal-title":"Cardiovasc Diabetol"},{"key":"1104_CR44","first-page":"121","volume":"7","author":"L Xu","year":"2018","unstructured":"Xu L, Ota T. Emerging roles of SGLT2 inhibitors in obesity and insulin resistance: focus on fat browning and macrophage polarization. Adipocyte. 2018;7:121\u20138.","journal-title":"Adipocyte"},{"key":"1104_CR45","doi-asserted-by":"publisher","first-page":"501","DOI":"10.2337\/dc19-1410","volume":"43","author":"A Avogaro","year":"2020","unstructured":"Avogaro A, Fadini GP, Del Prato S. Reinterpreting cardiorenal protection of renal sodium-glucose cotransporter 2 inhibitors via cellular life history programming. Diabetes Care. 2020;43:501\u20137.","journal-title":"Diabetes Care"},{"key":"1104_CR46","doi-asserted-by":"publisher","first-page":"508","DOI":"10.2337\/dci19-0074","volume":"43","author":"M Packer","year":"2020","unstructured":"Packer M. SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: a paradigm shift in understanding their mechanism of action. Diabetes Care. 2020;43:508\u201311.","journal-title":"Diabetes Care"},{"key":"1104_CR47","doi-asserted-by":"publisher","first-page":"107791","DOI":"10.1016\/j.diabres.2019.107791","volume":"155","author":"JPH Wilding","year":"2019","unstructured":"Wilding JPH, Rigney U, Blak BT, Nolan ST, Fenici P, Medina J. Glycaemic, weight, and blood pressure changes associated with early versus later treatment intensification with dapagliflozin in United Kingdom primary care patients with type\u00a02 diabetes mellitus. Diabetes Res Clin Pract. 2019;155:107791.","journal-title":"Diabetes Res Clin Pract"},{"key":"1104_CR48","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/S2213-8587(16)30267-4","volume":"4","author":"JP Fr\u00edas","year":"2016","unstructured":"Fr\u00edas JP, Guja C, Hardy E, et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type\u00a02 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2016;4:1004\u201316.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1104_CR49","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1111\/dom.13206","volume":"20","author":"SA Jabbour","year":"2018","unstructured":"Jabbour SA, Fr\u00edas JP, Guja C, Hardy E, Ahmed A, \u00d6hman P. Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type\u00a02 diabetes in the DURATION-8 study. Diabetes Obes Metab. 2018;20:1515\u20139.","journal-title":"Diabetes Obes Metab"},{"key":"1104_CR50","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/S2213-8587(18)30023-8","volume":"6","author":"B Ludvik","year":"2018","unstructured":"Ludvik B, Fr\u00edas JP, Tinahones FJ, et al. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type\u00a02 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2018;6:370\u201381.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1104_CR51","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/S2213-8587(19)30066-X","volume":"7","author":"B Zinman","year":"2019","unstructured":"Zinman B, Bhosekar V, Busch R, et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type\u00a02 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019;7:356\u201367.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1104_CR52","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jcjd.2019.06.004","volume":"44","author":"J Huynh","year":"2020","unstructured":"Huynh J, Menezes HT, Gerstein H, Sherifali D. Exploring the experiences of adults with type\u00a02 diabetes on sodium glucose cotransporter 2 inhibitors. Can J Diabetes. 2020;44:184\u201391.","journal-title":"Can J Diabetes"},{"key":"1104_CR53","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.jcjd.2019.04.004","volume":"43","author":"V Woo","year":"2019","unstructured":"Woo V, Bell A, Clement M, et al. CANadian CAnagliflozin REgistry: patient-reported outcomes of canagliflozin in the treatment of type\u00a02 diabetes mellitus in Canadian clinical practice. Can J Diabetes. 2019;43:464\u201371.","journal-title":"Can J Diabetes"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-021-01104-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-021-01104-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-021-01104-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T10:41:02Z","timestamp":1628160062000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-021-01104-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,9]]},"references-count":53,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["1104"],"URL":"https:\/\/doi.org\/10.1007\/s13300-021-01104-z","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,9]]},"assertion":[{"value":"15 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}